A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Phase 1
96
about 12 months
18–65
1 site in IL
About this study
This trial is testing a treatment called ABBV-295, given as subcutaneous injections, in adults with obesity. The goal is to see what side effects occur and how the body processes this medication.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ABBV-295
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Area under the plasma concentration-time curve (AUC) of ABBV-295, Dose Normalized AUC of ABBV-295, Dose Normalized Cmax of ABBV-295, Incidence of Anti-Drug Antibodies (ADAs), Maximum Observed Plasma Concentration (Cmax) of ABBV-295, Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements, Number of Participants with Adverse Events (AEs), Number of Participants with Change from Baseline in Electrocardiogram (ECG)
Endocrinology